title: Re: Samuel R. Denmeade, Blair Egerdie, Gary Steinhoff, et al. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011;59:747-54.
authors.forename: Tommaso
authors.initials: T
authors.lastname: Cai
authors.forename: Dalla Palma
authors.initials: DP
authors.lastname: Paolo
authors.forename: Gianni
authors.initials: G
authors.lastname: Malossini
mesh_terms: D001427:Bacterial Toxins / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007267:Injections; D008297:Male; D009336:Necrosis; D052899:Pore Forming Cytotoxic Proteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D011467:Prostate / Q000187:drug effects* / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D018570:Risk Assessment; D016896:Treatment Outcome; D014570:Urologic Diseases / Q000188:drug therapy* / Q000209:etiology
chemical_list: D001427:Bacterial Toxins; C518473:PRX302; D052899:Pore Forming Cytotoxic Proteins